Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.077,27-1,00 %

Gold3.370,08+0,03 %

Öl (Brent)78,65+3,08 %

Dow Jones41.772,52-0,91 %

US Tech 10021.477,37-1,08 %

EUR/USD1,14835-0,01 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Innate Pharma Aktie

Aktie

ISIN: FR0010331421 WKN: A0LCUJ SYM: IDD Land Flagge FR

Frankreich

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

1,6660

EUR

+0,12 %

+0,0020 EUR

Letzter Kurs 11:33:37 Tradegate

Innate Pharma Aktie kaufen

Geldkurs

20:12:18

1,6520

EUR

609 STK

Briefkurs

20:12:18

1,6660

EUR

597 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences 17.06.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress 13.06.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences 27.05.25 · Business Wire (engl.) · Innate Pharma
Outcome of Innate Pharma’s 2025 Annual General Meeting 23.05.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides 23.05.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting 19.05.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Highlights ANKET Abstracts Selected for the EHA 2025 Congress 15.05.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results 13.05.25 · Business Wire (engl.) · Innate Pharma
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025 12.05.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma announces conference call and webcast for Q1 2025 business update 06.05.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F 30.04.25 · Business Wire (engl.) · Innate Pharma
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting 29.04.25 · Business Wire (engl.) · Innate Pharma

1
2
3
…
4

Meistgelesen

7 Tage
30 Tage
12 Monate

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma ... 120 Leser
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare ... 116 Leser

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences 140 Leser
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides 128 Leser
Outcome of Innate Pharma’s 2025 Annual General Meeting 128 Leser
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma ... 120 Leser
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare ... 116 Leser

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From ... 172 Leser
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody ... 168 Leser
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed ... 168 Leser
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual ... 160 Leser
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 152 Leser
Innate Pharma Announces Transformative Strategy to Accelerate Growth 144 Leser
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences 140 Leser
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York 140 Leser
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results 140 Leser
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025 136 Leser